News Agency
Men's Weekly

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

  • Written by PR Newswire
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
  • ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology in the United States
  • The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL)

DOYLESTOWN, Pa., M...

Read more: Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Steps to Take When Facing a Commercial Lease Dispute in Australia

A commercial lease dispute can disrupt business operations, especially when the business premises are central to generating revenue. This article outlines practical steps to take when a disagreement arises under a commercial lease in Australia and how, as a tenant, you can... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion